TAI · 1734.TW
Sinphar Pharmaceutical Co. Ltd.
NT$30.55-NT$0.20 (-0.65%)
Sinphar Pharmaceutical Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.86% below the high.
Loading market information…
TAI · 4119.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
SCI Pharmtech, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.98% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
SCI Pharmtech, Inc.’s forward annual dividend is NT$0.75 per share, paid annual. The forward yield is 1.47% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
SCI Pharmtech, Inc.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of NT$0.34. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow SCI Pharmtech, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SCI Pharmtech, Inc., founded in 1987 and based in Taoyuan City, Taiwan, specializes in the comprehensive lifecycle of pharmaceutical components. The company's core operations involve the research and development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs), chemical intermediates, and specialty chemicals. Its extensive portfolio of APIs includes critical compounds such as Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Cannabidiol, and Dexmethylphenidate HCl, among many others. Additionally, SCI Pharmtech produces a wide array of intermediate products, featuring substances like Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Pyrogallolaldehyde, and various specialized esters and alcohols, which serve as essential building blocks in chemical synthesis. Beyond its standard product lines, the company also offers custom manufacturing services tailored to specific client needs. SCI Pharmtech maintains a robust international presence, distributing its products to significant markets across the globe, including Italy, China, the United States, Germany, Taiwan, Switzerland, Spain, Japan, and the Netherlands.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:00 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| NT$360.29M-2.62% vs estimate |
| Q4 2024 | Mar 10, 2025 | NT$0.39-36.38% vs estimate | NT$401.85M-6.11% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | NT$3.19+561.28% vs estimate | NT$419.29M+62.61% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$30.55-NT$0.20 (-0.65%)
Sinphar Pharmaceutical Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.86% below the high.
NT$45.40-NT$3.10 (-6.39%)
OBI Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.04% below the high.
NT$23.30-NT$0.20 (-0.85%)
Orient Pharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.28% below the high.
NT$127.00NT$0.00 (0.0%)
Hi-Clearance Inc.’s quoted price sits in the lower half of its reported 52-week range, 7.97% below the high.
NT$45.95-NT$0.55 (-1.18%)
Formosa Laboratories, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.82% below the high.
NT$75.50+NT$0.20 (+0.27%)
Pacific Hospital Supply Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 15.83% below the high.
NT$88.10-NT$0.40 (-0.45%)
Formosa Optical Technology Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.05% below the high.
NT$22.25-NT$0.25 (-1.11%)
Mycenax Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.86% below the high.
